New Myelofibrosis Research from University of Utah Discussed (A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis)

MLA

“New Myelofibrosis Research from University of Utah Discussed (A Phase 1, Open-Label, Dose-Escalation Study of Selinexor plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis).” Hematology Week, 26 June 2023, p. 3143. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.754677605&authtype=sso&custid=ns315887.

APA

New Myelofibrosis Research from University of Utah Discussed (A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis). (2023, June 26). Hematology Week, 3143.

Chicago

Hematology Week. 2023. “New Myelofibrosis Research from University of Utah Discussed (A Phase 1, Open-Label, Dose-Escalation Study of Selinexor plus Ruxolitinib in Patients with Treatment-Naive Myelofibrosis),” June 26. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.754677605&authtype=sso&custid=ns315887.